Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL18691787 | 0.98 | KMT2A (0.44) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL453632 | 0.96 | KMT2A (0.48) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL28161064 | 0.96 | KMT2A (0.48) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL30536400 | 0.96 | KMT2A (0.48) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| Phenol SCHEMBL11266550 | 0.91 | KMT2A (0.53) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| Sulfuric Acid SCHEMBL9326880 | 0.89 | CA1 (0.44) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL27977847 | 0.89 | KMT2A (0.43) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL5692314 | 0.83 | PARP1 (0.51) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| Acetic Acid SCHEMBL6125418 | 0.82 | HDAC1 (0.51) | KMT2AKDM4EMAPTPARP1GAA | |
| SCHEMBL7213300 | 0.81 | PARP1 (0.45) | KMT2AKDM4EMEN1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594350-B2 | CD8-specific capture agents, compositions, and methods of using and making | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12546785-B2 | IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making | REGENERON PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545733-B2 | Anti-CD103 antibodies | IMMIOS HOLDING B.V. (NL) | 2026-02-10 | — | — | US | disclosed |
| US-12517136-B2 | Il-17F-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250361298-A1 | LY6G6D BINDING PROTEINS, NUCLEIC ACIDS ENCODING SUCH PROTEINS, AND METHODS FOR THE PREPARATION AND USE THEREOF | CARTOGRAPHY BIOSCIENCES, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250130235-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2025-04-24 | — | — | US | disclosed |
| EP-3322716-B1 | IL-17F-SPECIFIC CAPTURE AGENTS AND METHODS OF USING | CALIFORNIA INST OF TECHN (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12216122-B2 | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) | REGENERON PHARMACEUTICALS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20250026790-A1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | REGENERON PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20240337665-A1 | IL-17F AND IL-17A-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | REGENERON PHARMACEUTICALS, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-1587944-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | Dyax Corp. (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050214859-A1 | Peptides that specifically bind HGF receptor (cMet) and uses thereof | DYAX CORP. | 2005-09-29 | — | — | US | disclosed |
| EP-1572724-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | Dyax Corp. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050100963-A1 | Multimeric protein comprising endothelial growth factor (VEGF) and kinase domain region (KDR) for use in detection, prevention and treatment of cell proliferative, virral and infectious disorders | DYAX CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
| EP-1458923-A2 | TREATMENT OF FABRIC ARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004078778-A2 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF | DYAX CORP. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004065621-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003074005-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030126690-A1 | Treatment of fabric articles with hydrophobic chelants | PROCTER & GAMBLE COMPANY, THE | 2003-07-10 | — | — | US | disclosed |
| WO-2003054278-A2 | TREATMENT OF FABRIC ARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12216122-B2 | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1) | IDO1, IDO2, KYNU | KMT2A 2344/4885KDM4E 2627/4885MEN1 210/4885 |
| US-20240337665-A1 | IL-17F AND IL-17A-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | IL17A, IL23R, IL15 | KMT2A 3646/4885KDM4E 3877/4885MEN1 1885/4885 |
| US-20250026790-A1 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | BTD, NPY1R, BTN3A1 | KMT2A 3204/4885KDM4E 3742/4885MEN1 815/4885 |
| US-12594350-B2 | CD8-specific capture agents, compositions, and methods of using and making | CD74, CD4, MICA | KMT2A 1486/4885KDM4E 1615/4885MEN1 4582/4885 |
| US-20250130235-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, PIK3CB, AKT3 | KMT2A 1771/4885KDM4E 3776/4885MEN1 767/4885 |
| US-12545733-B2 | Anti-CD103 antibodies | CD74, CD99, MALT1 | KMT2A 1021/4885KDM4E 3102/4885MEN1 975/4885 |
| US-12546785-B2 | IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making | IL17A, IL23R, IL36G | KMT2A 718/4885KDM4E 343/4885MEN1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.